Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Miyagi, Sendai, Japan Clinical Trials

A listing of Miyagi, Sendai, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (68) clinical trials

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), ...

Phase

0.0 miles

Learn More »

A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age

This is a study to confirm the efficacy of Levetiracetam as adjunctive treatment in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.

Phase

0.0 miles

Learn More »

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Participants considered an adult according to local regulation at the time of obtaining informed consent may participate in the study.

Phase

0.0 miles

Learn More »

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

This study evaluates the efficacy, safety, and tolerability of ustekinumab in participants with active SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score greater than (>=) 6, despite receiving one or more standard-of-care treatments (example, immunomodulators, antimalarial drugs, and/or glucocorticoids). ...

Phase

0.0 miles

Learn More »

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

This is a study of pembrolizumab (MK-3475, KEYTRUDA) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that ...

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Phase

0.0 miles

Learn More »

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

This is a Phase 3 clinical trial to compare the safety and efficacy of SyB P-1501 with the SyB P-1501 placebo for the management of the first 24 hours of post-operative pain.

Phase

0.0 miles

Learn More »

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-nave subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation ...

Phase

0.0 miles

Learn More »

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Study AG120-C-009 is a global, Phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of AG-120 (ivosidenib) + azacitidine vs placebo + azacitidine in adult subjects with previously untreated IDH1m AML who are considered appropriate candidates for non-intensive therapy. The primary endpoint is Overall Survival ...

Phase

0.0 miles

Learn More »

Clinical Benefit of SAR650984 Bortezomib Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant

The duration of the study for each patient will include a screening period of up to 4 weeks, an induction period of 24 weeks (4 cycles with a duration of 42 4 days), a continuous treatment period and a crossover period (when applicable). The cycle duration is 28 4 days ...

Phase

0.0 miles

Learn More »